Lipid transfer proteins and PI4KIIα initiate nuclear p53-phosphoinositide signaling Authors: Noah D. Carrillo, Mo Chen, Poorwa Awasthi, Tianmu Wen, Xue Yang, Colin Sterling, Dhruv Brahmbhatt, Vincent L. Cryns, Richard A. Anderson Published: 2026 ABSTRACT Phosphoinositide (PIPn) messengers are present in non-membranous regions of nuclei where they are assembled into a phosphatidylinositol (PI) 3-kinase (PI3K)/Akt pathway that is distinct from the cytosolic membrane-localized pathway. In one nuclear pathway, PI kinases/phosphatases bind the p53 tumor suppressor protein (wild-type and mutant) to generate p53-PIPn complexes (p53-PIPn signalosome) that activate Akt by a PI3,4,5P3-dependent mechanism in non-membranous regions of the nucleus. This pathway is dependent on a source of nuclear PIPns that is poorly characterized. Here we report that a subset of PI transfer proteins (PITPs), which transport PI between membranes to enable membrane-localized PIPn synthesis, also interact with p53 in the nucleus upon genotoxic stress. Class I PITPs (PITPα/β) specifically supply the PI required for the generation of p53-PIPn complexes and subsequent p53 signaling in the nucleus. The PI 4-kinase PI4KIIα binds to p53 and together with the PITPs are necessary for the formation of p53-PI4P. p53-PI4P is then sequentially phosphorylated to synthesize p53-PIPn complexes that regulate p53 stability, nuclear Akt activation and genotoxic stress resistance. In this pathway, PITPα/β and PI4KIIα bind p53 and collaborate to initiate p53-PIPn signaling by mechanisms that require PI transfer by PITPα/β and the catalytic activity of PI4KIIα. Moreover, the identification of these critical upstream regulators of p53-PIPn signaling point to PITPα/β and PI4KIIα as potential therapeutic targets in this pathway for mutant p53 driven cancers. Phosphoinositide (PIPn) lipids are synthesized from phosphatidylinositol (PI) in membranes by PIP-metabolizing enzymes, including kinases and phosphatases, to produce a second messenger network comprised of seven distinct isomers that play key roles in many cellular pathways (1). Cytosolic class I PI 3-kinases (PI3Ks) catalyze the synthesis of PI3,4,5P3, which leads to the recruitment and activation of the serine/threonine kinases phosphoinositide-dependent kinase 1 (PDK1), mTOR Complex 2 (mTORC2), and Akt at membranes (2, 3, 4, 5, 6, 7, 8). Akt in turn phosphorylates many substrates, such as forkhead box O (FOXO) proteins, tuberous sclerosis complex 2 (TSC2), and BCL2-associated agonist of cell death (BAD), to promote cell growth and inhibit apoptosis (4). This membrane-localized PI3K/Akt pathway is often hyperactivated in cancer and class I PI3K inhibitors are currently in the clinic (9, 10). Akt is also activated in the nucleus (11, 12, 13, 14, 15, 16). Recent studies have identified a non-membranous nuclear PI3K/Akt pathway dependent on p53 (17, 18), a tumor suppressor frequently mutated in cancer, resulting in gain-of-function oncogenic acitivities (19, 20). In this nuclear pathway, wild-type and mutant p53 are sequentially modified by PIPns and their associated PIP kinases/phosphatases. The type I PI4P 5-kinase α (PIPKIα) directly interacts with p53 and generates the p53-PI4,5P2 complex (p53-PIPn signalosome) in response to stress (18). PI5P4Kβ has also been functionally linked to p53 as deletion of both genes is lethal in mice, but the mechanism is poorly defined (21). The nuclear PI 3-kinase IPMK (inositol polyphosphate multikinase) acts on p53-PI4,5P2 to synthesize p53-PI3,4,5P3 complexes, which then recruit and activate Akt in the non-membranous nucleoplasm (17, 18). The nuclear Akt pathway is insensitive to PI3K inhibitors in the clinic (17), highlighting its therapeutic importance. Although multiple PIPns and PIP kinases/phosphatases are present in the nucleoplasm (16, 22, 23, 24), their function and regulation are poorly characterized compared to PIPn signaling at cytosolic membranes. Specifically, prior studies have demonstrated the synthesis of PI in the ER, which is transported from the ER to other membranes, and shuttled between membranes by a family of lipid transfer proteins, the phosphatidylinositol transfer proteins (PITPs) (25). To date, research has focused on the cytosolic function of PITPs (26, 27, 28). Intriguingly, PITPβ was suggested to interact with p53 (29), prompting us to investigate the functional role of PITPs in regulating the synthesis of p53-PIPn complexes. Here we demonstrate that the highly homologous class I PITPs interact with p53 in the nucleus upon genotoxic stress and are specifically required to generate p53-PIPn complexes. Additionally, a PI 4-kinase, PI4KIIα, binds to both p53 and the PITPs and is also required to initiate p53-PIPn complex formation and nuclear p53-PIPn signaling. PITPα/β and PI4KIIα collaborate to synthesize p53-PI4P complexes that are sequentially phosphorylated by PIP kinases or dephosphorylated by phosphatases to regulate p53 stability, nuclear Akt activation and stress resistance. These findings also implicate PITPα/β and PI4KIIα as therapeutic targets to regulate the nuclear p53-PIPn pathway. Results p53 interacts with class I PITPs in the nucleus The reported interaction of PITPβ and p53 in a proteomic screen (29) suggests that PITPs may play a role in generating nuclear p53-PIPn complexes. To explore this, we investigated the interaction of p53 with PITPs using multiple approaches. The PITP family is composed of five members that are subdivided into two classes that exchange PI for PC (Class I, the single domain PITPα and PITPβ isoforms) or PI for phosphatidic acid (PA) (Class II, the single domain PITP cytoplasmic 1 (PITPNC1) and the multi-domain PITP membrane-associated 1 and 2 (PITPNM1 and PITPNM2) isoforms with C-terminal extensions) (25) (Fig. 1A). The PITP-p53 interactions were first examined by immunoprecipitation (IP). Class I, but not class II PITPs, bound mutant p53 (p53mt), and these interactions were increased by genotoxic stress (Fig. 1, B–D, F and G). Of note, the PITPα antibody had partial cross-reactivity with PITPβ but not beyond the class I PITPs (Fig. S1A). These IP interactions were recapitulated by in vitro binding studies with recombinant PITPα/β and p53 proteins, demonstrating a high-affinity, saturable binding of class I PITPs to p53 (Fig. S1, B–E). Moreover, the small heat shock proteins (sHSPs) Hsp27 and αB-crystallin, which stabilize the p53-PIPn complex (18), were also detected as stress-regulated components of the PITPα/β-p53 complex (Fig. 1, B, E, F, H and I).Figure 1p53 interacts with the PITPs in the nucleus upon stress.A, Domains of PITP class I and II protein family members. PITD, PI transfer domain; FFAT, two phenylalanines in an acidic tract; DDHD, Asp-Asp-His-Asp motif; LNS2, Lipin/Nde1/Smp2 domain. B–E, Co-IP of PITPα/PITPβ/Hsp27 with p53 from MDA-MB-231 cells treated with vehicle or 30 μM cisplatin for 24 h. PITPα IP-ed by p53 (C), PITPβ IP-ed by p53 (D), and Hsp27 IP-ed by p53 (E), as well as PITPNC1/PITPNM1/PITPNM2 were analyzed by WB. p value denotes two-sided paired t test. F–I, Co-IP of p53/Hsp27/αB-crystallin (αBC) with the shared epitope of PITPα/β from MDA-MB-231 cells treated with vehicle or 30 μM cisplatin for 24 h p53 IP-ed by PITPα/β (G), Hsp27 IP-ed by PITPα/β (H), and αBC IP-ed by PITPα/β (i) were analyzed by WB. p value denotes two-sided paired t test. J–K, PLA of p53-PITPα/PITPβ/PITPNC1/PITPNM1/PITPNM2 in MDA-MB-231 cells treated with vehicle or 30 μM cisplatin for 24 h. The nuclear p53-PITP foci were quantified (K). n = 3, average values were calculated from ten cells from each independent experiment. p value denotes two-sided paired t test. See expanded images in Fig. S2A. l, PLA of p53-PITPα/PITPβ/PITPNC1/PITPNM1/PITPNM2 overlaid with the nuclear envelope marker Lamin A and C in MDA-MB-231 cells treated with vehicle or 30 μM cisplatin for 24 h. The nuclei were counterstained by DAPI. See expanded images in Fig. S2E. M, Co-IP of PITPα/PITPβ with p53 in BT549, Cal33, HS578T, SUM159, SUM1315 cells treated with vehicle or 30 μM cisplatin for 24 h. PITPα/PITPβ IPed by p53 (N) and PITPNC1/PITPNM1/PITPNM2 were analyzed by WB. See expanded images in Fig. S3, J–N. For all panels, n = 3 independent experiments. p53 interacts with the PITPs in the nucleus upon stress.A, Domains of PITP class I and II protein family members. PITD, PI transfer domain; FFAT, two phenylalanines in an acidic tract; DDHD, Asp-Asp-His-Asp motif; LNS2, Lipin/Nde1/Smp2 domain. B–E, Co-IP of PITPα/PITPβ/Hsp27 with p53 from MDA-MB-231 cells treated with vehicle or 30 μM cisplatin for 24 h. PITPα IP-ed by p53 (C), PITPβ IP-ed by p53 (D), and Hsp27 IP-ed by p53 (E), as well as PITPNC1/PITPNM1/PITPNM2 were analyzed by WB. p value denotes two-sided paired t test. F–I, Co-IP of p53/Hsp27/αB-crystallin (αBC) with the shared epitope of PITPα/β from MDA-MB-231 cells treated with vehicle or 30 μM cisplatin for 24 h p53 IP-ed by PITPα/β (G), Hsp27 IP-ed by PITPα/β (H), and αBC IP-ed by PITPα/β (i) were analyzed by WB. p value denotes two-sided paired t test. J–K, PLA of p53-PITPα/PITPβ/PITPNC1/PITPNM1/PITPNM2 in MDA-MB-231 cells treated with vehicle or 30 μM cisplatin for 24 h. The nuclear p53-PITP foci were quantified (K). n = 3, average values were calculated from ten cells from each independent experiment. p value denotes two-sided paired t test. See expanded images in Fig. S2A. l, PLA of p53-PITPα/PITPβ/PITPNC1/PITPNM1/PITPNM2 overlaid with the nuclear envelope marker Lamin A and C in MDA-MB-231 cells treated with vehicle or 30 μM cisplatin for 24 h. The nuclei were counterstained by DAPI. See expanded images in Fig. S2E. M, Co-IP of PITPα/PITPβ with p53 in BT549, Cal33, HS578T, SUM159, SUM1315 cells treated with vehicle or 30 μM cisplatin for 24 h. PITPα/PITPβ IPed by p53 (N) and PITPNC1/PITPNM1/PITPNM2 were analyzed by WB. See expanded images in Fig. S3, J–N. For all panels, n = 3 independent experiments. Proximity ligation assay (PLA) is an established approach to detect protein-protein interactions and posttranslational modifications (PTMs) in situ (30, 31). Class I PITPs (PITPα and PITPβ), but not class II PITPs (PITPNCI, PITPNM1, and PITPNM2), associated with p53mt and wild-type p53 (p53wt) in the nucleus as indicated by PLA foci, and their association was enhanced by cisplatin (Figs. 1, J and K and S2, A–C). Interestingly, PITPα/β-p53 PLA complexes were present in the nucleoplasm in regions distinct from the nuclear envelope (Figs. 1L and S2, D–F, and Videos S1 and S2). Despite their previously reported confinement to the cytosol (25, 26), PITPα/β were observed in the nuclear fraction under basal conditions, and genotoxic stress increased their nuclear accumulation, consistent with the PLA data (Fig. S3A). Notably, the association of PITPα/β with p53wt was minimal under basal conditions and dramatically increased by stress (Fig S3, B and C), while PITPα/β associated constitutively with p53mt with a modest increase in response to stress. To determine the level of conservation for this pathway and the potential impact p53 mutations may have on the interaction with PITPα/β, we repeated this experiment in a panel of cell lines from various tissue origins and harboring independent hotspot mutations with clinical prevalence (32), functional significance (33, 34, 35) or that have modifications in interactions with PIPns (17, 18). Regardless of p53 mutational status, stress-responsive PITPα/β-p53 complexes were detected in all cell lines examined (Figs. 1M and S3, B–N). Moreover, p53 directly bound class I PITPs, but not PITPNC1, with high affinity, low nM Kd, as determined by microscale thermophoresis (MST) (Table 1 and Fig. S4), underscoring the specificity of these interactions.Figure 2PITPα/β regulate p53-PIPn complexes.A–C, MDA-MB-231 cells were transfected with control siRNAs or siRNAs against p53, PITPα, PITPβ, PITPNC1, or both PITPα and PITPβ. After 24 h, cells were treated with 30 μM cisplatin or vehicle for 24 h before being processed for PLA to detect p53-PI4,5P2/-PI3,4,5P3 complexes (B and C). n = 3, average values were calculated from ten cells from each independent experiment. p value denotes ANOVA with Bonferroni's multiple comparisons test. See KD validation in Fig. S5D and expanded images in Fig. S5, A and B. D–F, A549 cells were transfected with control siRNAs or siRNAs against PITPα, PITPβ, or both PITPα and PITPβ. After 24 h, cells were treated with 30 μM cisplatin or vehicle for 24 h before being processed for PLA to detect p53-PI4,5P2/PI3,4,5P3 complexes (E and F). n = 3, average values were calculated from ten cells from each independent experiment. p value denotes ANOVA with Bonferroni's multiple comparisons test. See KD validation in Fig. S5G. G, MDA-MB-231 cells were treated with 30 μM cisplatin or vehicle for 24 h before being processed for IP against p53. p53-bound PI4P/PI4,5P2/PI3,4,5P3 were examined by fluorescent WB. See quantification in Fig. S5C. H–K, MDA-MB-231 cells were transfected with control siRNAs or siRNAs against PITPα, PITPβ, or both PITPα and PITPβ. After 24 h, cells were treated with 30 μM cisplatin or vehicle for 24 h before being processed for IP against p53. p53-bound PI4P/PI4,5P2/PI3,4,5P3 were examined by fluorescent WB and quantified by ImageJ (I–K). p value denotes ANOVA with Bonferroni's multiple comparisons test. L and M, A549 cells were transfected with control siRNAs or siRNAs against PITPα, PITPβ, or both PITPα and PITPβ. After 24 h, cells were treated with 30 μM cisplatin or vehicle for 24 h before being processed for IP against p53. The PI4,5P2 level on IPed p53 was quantified by ImageJ (M). p value denotes ANOVA with Bonferroni's multiple comparisons test. For all panels, n = 3 independent experiments and data are represented as mean ± SD. Scale bar, 5 μm.Table 1MST analysis of p53 and PITPs, The interaction of recombinant fluorescently labelled p53 with other components was quantitated by MST assayMicroscale thermophoresis (MST)Target ProteinBinding affinity with p53 (Kd) PITPα1.95 ± 1 nM PITPα + PI (1μM)16 ± 1 nM PITPβ19 ± 1 nM PITPβ + PI (1μM)5 ± 1 nM PITPNC1NBDA constant concentration of fluorescently labelled p53 (5 nM) was incubated with increasing concentrations of non-labelled ligand with or without the addition of 1 μM PI (micelles) and analyzed using a Monolith NT.115 pico, and the binding affinity was autogenerated by MO. Control v.1.6 software. Data are presented as the mean ± SD. NBD=No Binding Detected. PITPα/β regulate p53-PIPn complexes.A–C, MDA-MB-231 cells were transfected with control siRNAs or siRNAs against p53, PITPα, PITPβ, PITPNC1, or both PITPα and PITPβ. After 24 h, cells were treated with 30 μM cisplatin or vehicle for 24 h before being processed for PLA to detect p53-PI4,5P2/-PI3,4,5P3 complexes (B and C). n = 3, average values were calculated from ten cells from each independent experiment. p value denotes ANOVA with Bonferroni's multiple comparisons test. See KD validation in Fig. S5D and expanded images in Fig. S5, A and B. D–F, A549 cells were transfected with control siRNAs or siRNAs against PITPα, PITPβ, or both PITPα and PITPβ. After 24 h, cells were treated with 30 μM cisplatin or vehicle for 24 h before being processed for PLA to detect p53-PI4,5P2/PI3,4,5P3 complexes (E and F). n = 3, average values were calculated from ten cells from each independent experiment. p value denotes ANOVA with Bonferroni's multiple comparisons test. See KD validation in Fig. S5G. G, MDA-MB-231 cells were treated with 30 μM cisplatin or vehicle for 24 h before being processed for IP against p53. p53-bound PI4P/PI4,5P2/PI3,4,5P3 were examined by fluorescent WB. See quantification in Fig. S5C. H–K, MDA-MB-231 cells were transfected with control siRNAs or siRNAs against PITPα, PITPβ, or both PITPα and PITPβ. After 24 h, cells were treated with 30 μM cisplatin or vehicle for 24 h before being processed for IP against p53. p53-bound PI4P/PI4,5P2/PI3,4,5P3 were examined by fluorescent WB and quantified by ImageJ (I–K). p value denotes ANOVA with Bonferroni's multiple comparisons test. L and M, A549 cells were transfected with control siRNAs or siRNAs against PITPα, PITPβ, or both PITPα and PITPβ. After 24 h, cells were treated with 30 μM cisplatin or vehicle for 24 h before being processed for IP against p53. The PI4,5P2 level on IPed p53 was quantified by ImageJ (M). p value denotes ANOVA with Bonferroni's multiple comparisons test. For all panels, n = 3 independent experiments and data are represented as mean ± SD. Scale bar, 5 μm. Table 1MST analysis of p53 and PITPs, The interaction of recombinant fluorescently labelled p53 with other components was quantitated by MST assayMicroscale thermophoresis (MST)Target ProteinBinding affinity with p53 (Kd) PITPα1.95 ± 1 nM PITPα + PI (1μM)16 ± 1 nM PITPβ19 ± 1 nM PITPβ + PI (1μM)5 ± 1 nM PITPNC1NBDA constant concentration of fluorescently labelled p53 (5 nM) was incubated with increasing concentrations of non-labelled ligand with or without the addition of 1 μM PI (micelles) and analyzed using a Monolith NT.115 pico, and the binding affinity was autogenerated by MO. Control v.1.6 software. Data are presented as the mean ± SD. NBD=No Binding Detected. MST analysis of p53 and PITPs, The interaction of recombinant fluorescently labelled p53 with other components was quantitated by MST assay A constant concentration of fluorescently labelled p53 (5 nM) was incubated with increasing concentrations of non-labelled ligand with or without the addition of 1 μM PI (micelles) and analyzed using a Monolith NT.115 pico, and the binding affinity was autogenerated by MO. Control v.1.6 software. Data are presented as the mean ± SD. NBD=No Binding Detected. PITPα/β are required for p53-PIPn complex generation As PITPα/β bind to p53 in the nucleus, we examined the potential role of PITPα/β in regulating the PIPn associations with p53, which stabilize p53 (18). The p53-PIPn complexes (17, 18) were first analyzed by PLA. Single or combined knockdown (KD) of PITPα/β, but not PITPNC1, reduced or largely eliminated, respectively, p53mt-PI4,5P2 and p53mt-PI3,4,5P3 complexes detected by PLA; combined KD of PITPα/β disrupted p53mt-PIPn complexes to a similar degree as p53 KD (Figs. 2, A–C and S5, A and B). Similar results were observed in p53wt cells: individual or combined PITPα/β KD inhibited p53wt-PI4,5P2 and p53wt-PI3,4,5P3 complexes (Fig. 2, D–F). We next identified and quantified the cisplatin-induced PIPn isoforms linked to p53 by p53-IP followed by simultaneous Western blotting (WB) with antibodies (Abs) against specific PIPn isomers detected with fluorescently labeled secondary Abs (IP fluorescent-WB) (Figs. 2G and S5C). KD of PITPα or PITPβ markedly reduced the PI4P, PI4,5P2 and PI3,4,5P3 that co-IPed with p53mt in response to genotoxic stress, while the combined KD virtually eliminated all PIPns associated with p53mt (Fig. 2, H–K). Similar observations were made in cells with p53wt: single or combined PITPα/β KD also inhibited cisplatin-stimulated p53wt-PI4,5P2 complex formation (Fig. 2, L and M). Consistent with the reported role of PIPns in stabilizing p53 (18), KD of PITPα or PITPβ, but not PITPNC1, modestly reduced p53mt levels in cells treated with cisplatin, while the combined KD of PITPα and PITPβ robustly suppressed p53mt levels under basal and stress conditions without impacting TP53 mRNA levels (Fig. S5, D and E). Reduced p53 levels after combined PITPα/β KD were not rescued by the MDM2 inhibitor Nutlin 3a (36), suggesting a MDM2-independent mechanism (Fig. S5F). Moreover, the robust induction of p53wt by cisplatin was inhibited by individual PITPα/β KD and abolished by the combined PITPα/β KD (Fig. S5G). The PIPn antibody approach was confirmed using radiolabeled [3H]-inositol, which is specifically incorporated into PI and then PIPns and inositol phosphates (37). [3H]-inositol was added to the culture media and p53 was IPed from these cells, resolved via WB, and excised from the gel, resulting in closely overlapping antibody reactivity and [3H]-inositol incorporation (Figs. 3, A and B and S5H). These findings indicate that class I PITPα and PITPβ are necessary for the stress-responsive coupling of PIPns to p53wt and p53mt proteins. The p53-associated PIPn, identifiable by both PIPn monoclonal antibody and [3H]-inositol labeling that persists after denaturation and SDS-PAGE analysis, establishes a unique and stable protein-lipid complex.Figure 3p53-PIPn complexes are validated by [3H]-inositol lableing.A and B, MDA-MB-231 cells were cultured from low confluency in media containing [3H]myo-inositol or unlabeled myo-inositol. After 72 h of growth to confluency, cells were treated with 30 μM cisplatin or vehicle for 24 h before being processed for IP against p53. p53 and PI4,5P2 were confirmed by fluorescent WB (A) before samples were resolved by SDS-PAGE and the gel lane was excised and sectioned. Gel sections were then dissolved and analyzed by liquid scintillation counting (LSC) (B). See experimental model in Fig. S5H. n = 3 independent experiments, error bar denotes SD, t test, p < 0.01∗, p < 0.001∗∗. For all graphs, data are presented as the mean ± SD. p53-PIPn complexes are validated by [3H]-inositol lableing.A and B, MDA-MB-231 cells were cultured from low confluency in media containing [3H]myo-inositol or unlabeled myo-inositol. After 72 h of growth to confluency, cells were treated with 30 μM cisplatin or vehicle for 24 h before being processed for IP against p53. p53 and PI4,5P2 were confirmed by fluorescent WB (A) before samples were resolved by SDS-PAGE and the gel lane was excised and sectioned. Gel sections were then dissolved and analyzed by liquid scintillation counting (LSC) (B). See experimental model in Fig. S5H. n = 3 independent experiments, error bar denotes SD, t test, p < 0.01∗, p < 0.001∗∗. For all graphs, data are presented as the mean ± SD. PI4KIIα interacts with p53 and cooperates with PITPα/β to synthesize p53-PI4P As PITPα/β were reported to cooperate with PI 4-kinases (PI4Ks) to synthesize PI4P (25, 38, 39), we postulated that PI4Ks act in concert with PITPα/β to generate p53-PI4P. To explore this, each of the four human PI4Ks (40) was individually KDed and PLA was used to quantify changes in the p53-PI4P complexes. KD of PI4KIIα specifically suppressed basal and cisplatin-stimulated p53-PI4P levels, while combined KD of PI4KIIα and PI4KIIIα reduced p53-PI4P levels to the same degree as PI4KIIα KD alone (Figs. 4, A and B and S6A). p53-PI4P is the substrate for PIPKIα to synthesize p53-PI4,5P2, which stabilizes p53 (18). Consistent with its role in generating p53-PI4P, PI4KIIα KD, but not KD of other PI4Ks, inhibited cisplatin-stimulated p53 levels (Fig. 4C). Moreover, KD of PI4KIIα mirrored the effects of PIPKIα KD in suppressing p53 induction by cisplatin, and combined KD of PI4KIIα and PIPKIα was equivalent to either individual KD regarding p53 levels (Fig. 4D). In contrast to PI4KIIα KD, which reduced p53-PI4P levels, KD of PIPKIα enhanced p53-PI4P levels (Fig. 4, E and F and S6B). p53-PI4P synthesis required the catalytic activity of PI4KIIα as the PI4KIIα inhibitors (PI-273 and NC03) (41, 42) prevented p53-PI4P generation and subsequent formation of p53-PI4,5P2 (Fig. 4G and S6, C–E).Figure 4PI4KIIα interacts with p53 to generate p53-PI4P complexes.A–B, MDA-MB-231 cells were transfected with control siRNAs or siRNAs against PI4KIIIα, PI4KIIIβ, PI4KIIα, PI4KIIβ or both PI4KIIα and PI4KIIIα. After 24 h, cells were treated with 30 μM cisplatin or vehicle for 24 h before being processed for PLA to detect p53-PI4P complexes (B). n = 3, average values were calculated from 15 cells from each independent experiment. p value denotes ANOVA with Bonferroni's multiple comparisons test. See KD confirmation in Figure 4C and expanded images in Figure 6A. C, MDA-MB-231 cells were transfected with control siRNAs or siRNAs against PI4KIIIα, PI4KIIIβ, PI4KIIα, PI4KIIβ or both PI4KIIα and PI4KIIIα. After 24 h, cells were treated with 30 μM cisplatin or vehicle for 24 h before being processed for WB. p53 levels were quantified by ImageJ. p value denotes ANOVA with Bonferroni's multiple comparisons test. D, A549 and MDA-MB-231 cells were transfected with control siRNAs or siRNAs against PI4KIIIα, PIPKIα or both PI4KIIα and PIPKIα. After 24 h, cells were treated with 30 μM cisplatin or vehicle for 24 h before being processed for WB. p53 levels were quantified by ImageJ. p value denotes ANOVA with Bonferroni's multiple comparisons test. E and F, MDA-MB-231 and A549 cells were transfected with control siRNAs or siRNAs against PI4KIIIα, PIPKIα or both PI4KIIα and PIPKIα. After 24 h, cells were treated with 30 μM cisplatin or vehicle for 24 h before being processed for PLA to detect p53-PI4P complexes. n = 3, average values were calculated from 15 cells from each independent experiment. p value denotes ANOVA with Bonferroni's multiple comparisons test. See KD confirmation in Figure 4D and expanded images in Fig. S6B. G, MDA-MB-231 cells were treated with vehicle or cisplatin in combination with DMSO as a control, PI-273, or NC03 for 24 h before being processed for PLA to detect p53-PI4,5P2 complexes and analyzed using ImageJ. n = 3, average values were calculated from 15 cells from each independent experiment. p value denotes two-sided paired t test. See expanded images in Fig. S6E. H, MDA-MB-231 and A549 cells were treated with 30 μM cisplatin or vehicle for 24 h before being processed for IP against p53. The PI4KIIIα, PI4KIIIβ, PI4KIIα, and PI4KIIβ levels IPed with p53 were analyzed by WB. I, MDA-MB-231Cas9 cells with PITPβ KO and control non-targeted KO were transfected with control siRNAs or siRNAs against PI4KIIα, PITPα, or both PI4KIIα and PITPα. After 24 h, cells were treated with 30 μM cisplatin or vehicle for 24 h before being processed for WB. J, model showing PITPα/β cooperation with PI4KIIα in generating p53-PI4P complexes that participate in further signaling. For all panels, n = 3 independent experiments and data are represented as mean ± SD. Scale bar, 5 μm. PI4KIIα interacts with p53 to generate p53-PI4P complexes.A–B, MDA-MB-231 cells were transfected with control siRNAs or siRNAs against PI4KIIIα, PI4KIIIβ, PI4KIIα, PI4KIIβ or both PI4KIIα and PI4KIIIα. After 24 h, cells were treated with 30 μM cisplatin or vehicle for 24 h before being processed for PLA to detect p53-PI4P complexes (B). n = 3, average values were calculated from 15 cells from each independent experiment. p value denotes ANOVA with Bonferroni's multiple comparisons test. See KD confirmation in Figure 4C and expanded images in Figure 6A. C, MDA-MB-231 cells were transfected with control siRNAs or siRNAs against PI4KIIIα, PI4KIIIβ, PI4KIIα, PI4KIIβ or both PI4KIIα and PI4KIIIα. After 24 h, cells were treated with 30 μM cisplatin or vehicle for 24 h before being processed for WB. p53 levels were quantified by ImageJ. p value denotes ANOVA with Bonferroni's multiple comparisons test. D, A549 and MDA-MB-231 cells were transfected with control siRNAs or siRNAs against PI4KIIIα, PIPKIα or both PI4KIIα and PIPKIα. After 24 h, cells were treated with 30 μM cisplatin or vehicle for 24 h before being processed for WB. p53 levels were quantified by ImageJ. p value denotes ANOVA with Bonferroni's multiple comparisons test. E and F, MDA-MB-231 and A549 cells were transfected with control siRNAs or siRNAs against PI4KIIIα, PIPKIα or both PI4KIIα and PIPKIα. After 24 h, cells were treated with 30 μM cisplatin or vehicle for 24 h before being processed for PLA to detect p53-PI4P complexes. n = 3, average values were calculated from 15 cells from each independent experiment. p value denotes ANOVA with Bonferroni's multiple comparisons test. See KD confirmation in Figure 4D and expanded images in Fig. S6B. G, MDA-MB-231 cells were treated with vehicle or cisplatin in combination with DMSO as a control, PI-273, or NC03 for 24 h before being processed for PLA to detect p53-PI4,5P2 complexes and analyzed using ImageJ. n = 3, average values were calculated from 15 cells from each independent experiment. p value denotes two-sided paired t test. See expanded images in Fig. S6E. H, MDA-MB-231 and A549 cells were treated with 30 μM cisplatin or vehicle for 24 h before being processed for IP against p53. The PI4KIIIα, PI4KIIIβ, PI4KIIα, and PI4KIIβ levels IPed with p53 were analyzed by WB. I, MDA-MB-231Cas9 cells with PITPβ KO and control non-targeted KO were transfected with control siRNAs or siRNAs against PI4KIIα, PITPα, or both PI4KIIα and PITPα. After 24 h, cells were treated with 30 μM cisplatin or vehicle for 24 h before being processed for WB. J, model showing PITPα/β cooperation with PI4KIIα in generating p53-PI4P complexes that participate in further signaling. For all panels, n = 3 independent experiments and data are represented as mean ± SD. Scale bar, 5 μm. To further define these p53-PIPn complexes, we utilized a p53 C-terminal domain (CTD) polybasic domain mutant (p536Q), which disrupts PI4,5P2 binding to p53 (wild-type and oncogenic mutants) (17, 18). In this context, the p536Q mutant formed more abundant p536Q -PI4P complexes than the corresponding wild-type CTD domain p53 proteins (Fig. S7, A and B). However, the p536Q -PI4P complexes were not phosphorylated further to p536Q -PI3,4,5P3 complexes (Fig. S7, C and D), likely due to disrupted binding of PIPKIα and/or IPMK, which interact with the p53 C-terminus (17, 18). Conventional PIPn binding to p53 relies on electrostatic interactions between a polybasic and positively charged surface of p53 and the negatively charged headgroup of the PIPn. This interaction encompasses the PIPn headgroup and is ablated by denaturing conditions. The p536Q mutant loses key basic amino acids in the CTD and disrupts conventional PIPn binding (18). However, the stable PI4P association with p53 is enhanced by the p536Q mutation as determined by PLA, persists through denaturation as demonstrated by WB, and retains headgroup accessibility and signaling competency as previously shown (17), indicating that these basic residues in the CTD are not required for the PIPn linkage to p53. The p536Q -PI4P and p53-PI4P complexes are mostly cytosolic, indicating that the PIP-linkage can be formed in the cytosol, consistent with results presented in the companion paper (43). In addition, PI4KIIα co-IPed with p53mt and p53wt, and these interactions were enhanced by genotoxic stress (Fig. 4H). PI4KIIIα co-IPed with p53mt and p53wt (Fig. 4H) but PI4KIIIα KD did not affect p53 or p53-PI4P levels or enhance the effects of PI4KIIα KD (Fig. 4, A–C). Recombinant PI4KIIα bound p53, PITPα, and PITPβ with saturable kinetics and low nM affinity (Fig. S8, A–C and Table 2), consistent with a specific and direct interaction. Interestingly, the PI4KIIα-PITPβ interaction was enhanced by the addition of p53, indicating a ternary PI4KIIα:PITPβ:p53 protein complex (Figs. 4I and S8, D and E). These findings indicate that PI4KIIα binds to p53 with high affinity, and together with PITPα/β, is necessary for the specific synthesis of p53-PI4P that contributes to p53 stabilization by generating the precursor for p53-PI4,5P2 (Fig. 4J).Table 2MST analysis of PI4KIIα, The interaction of recombinant fluorescently labelled PI4KIIα with other components was quantitated by MST assayMicroscale thermophoresis (MST)Target ProteinBinding affinity with PI4KIIα (Kd) p538 ± 1 nM PITPα189 ± 26 nM PITPα + PI (1μM)16 ± 2 nM PITPβ263 ± 12 nM PITPβ + PI (1μM)113 ± 11 nMA constant concentration of fluorescently labelled PI4KIIα (5 nM) was incubated with increasing concentrations of non-labelled ligand with or without the addition of 1 μM PI (micelles) and analyzed using a Monolith NT.115 pico, and the binding affinity was autogenerated by MO. Control v.1.6 software. The binding affinities determined by MST are shown as indicated Kd values. n = 3 independent experiments. Table 2MST analysis of PI4KIIα, The interaction of recombinant fluorescently labelled PI4KIIα with other components was quantitated by MST assayMicroscale thermophoresis (MST)Target ProteinBinding affinity with PI4KIIα (Kd) p538 ± 1 nM PITPα189 ± 26 nM PITPα + PI (1μM)16 ± 2 nM PITPβ263 ± 12 nM PITPβ + PI (1μM)113 ± 11 nMA constant concentration of fluorescently labelled PI4KIIα (5 nM) was incubated with increasing concentrations of non-labelled ligand with or without the addition of 1 μM PI (micelles) and analyzed using a Monolith NT.115 pico, and the binding affinity was autogenerated by MO. Control v.1.6 software. The binding affinities determined by MST are shown as indicated Kd values. n = 3 independent experiments. MST analysis of PI4KIIα, The interaction of recombinant fluorescently labelled PI4KIIα with other components was quantitated by MST assay A constant concentration of fluorescently labelled PI4KIIα (5 nM) was incubated with increasing concentrations of non-labelled ligand with or without the addition of 1 μM PI (micelles) and analyzed using a Monolith NT.115 pico, and the binding affinity was autogenerated by MO. Control v.1.6 software. The binding affinities determined by MST are shown as indicated Kd values. n = 3 independent experiments. PITPα/β regulate p53-PIPn signalosome formation and nuclear Akt activation to inhibit stress-induced apoptosis The p53-PIPn signalosome is regulated by cellular stress, leading to the formation of p53-PI3,4,5P3 complexes that recruit and activate Akt in the nucleus and protect cells from stress-induced apoptosis (17). The identification of class I PITPs as upstream regulators of p53-PIPn complex assembly implicates these lipid transfer proteins in nuclear Akt activation. Consistent with this concept, individual KD of PITPα or PITPβ, but not PITPNC1, suppressed stress-induced nuclear Akt activation quantified by nuclear pAktS473 IF, an established approach (17), while combined PITPα/β KD resulted in a more robust reduction of pAktS473 (Fig. 5, A and B). These results were confirmed in MDA-MB-231 cells by WB (Fig. S9A). Similar results were obtained with multiple human cancer cell lines expressing different p53mt proteins (Fig. 5, C–E). KD of p53mt, PITPα or PITPβ, but not PITPNC1, moderately reduced cell viability under basal conditions and sensitized MDA-MB-231 cells to cisplatin treatment, while combined KD of PITPα/β further decreased cell viability (Fig. 5, F and G). Consistent with these results, knockout (KO) of PITPβ or KD of PITPα had modest effects on cisplatin-induced cell death, while combined PITPβ KO and PITPα KD enhanced the cytotoxicity of cisplatin (Figs. 5H and S9B). Individual or combined PITPα/β KD had similar effects on cisplatin sensitivity in four additional breast cancer cell lines expressing different p53mt or p53wt proteins (Fig. S9, C–J). The cytotoxicity of p53mt KD and individual or combined PITPα/β KD was associated with a corresponding increase in caspase 3 activity (Figs. 5I and S9, K–M), indicating that PITPα/β KD triggers apoptosis and sensitizes cells to genotoxic stress. These findings underscore the critical role of PITPα/β in regulating nuclear Akt activation, which confers resistance to genotoxic stress-induced apoptosis.Figure 5PITPα/β regulate p53-dependent nuclear Akt activation and cell survival.A and B, MDA-MB-231 cells were transfected with control siRNAs or siRNAs against PITPα, PITPβ, PITPNC1, or both PITPα and PITPβ. After 24 h, cells were treated with 30 μM cisplatin or vehicle for 24 h before being processed for IF staining against pAktS473. The nuclear pAktS473 levels were quantified by ImageJ (B). n = 3, average values were calculated from 15 cells from each independent experiment. p value denotes ANOVA with Bonferroni's multiple comparisons test. Scale bar, 5 μm. C–E, BT-549, SUM159, and SUM1315 cells with the indicated p53 status were transfected with control siRNAs or siRNAs against both PITPα and PITPβ. After 24 h, cells were treated with 30 μM cisplatin or vehicle for 24 h before being processed for IF staining against pAktS473. The nuclei were counterstained by DAPI. The nuclear pAktS473 levels were quantified by ImageJ (D). n = 3, average values were calculated from 15 cells from each independent experiment. Scale bar, 5 μm. The double KD of PITPα and PITPβ in SUM159 cells was validated by WB (E). See KD validation for BT-549 and SUM1315 cells in Fig. S9, H and J. F and G, MDA-MB-231 cells were transfected with control siRNAs or siRNAs against p53, PITPα, PITPβ, PITPNC1, or both PITPα and PITPβ. After 24 h, cells were treated with 30 μM cisplatin or vehicle for 24 h before being processed for Crystal Violet viability assay. The cells were imaged by an EVOS M5000 microscope (F) and quantified based on the extracted dye using a plate reader (G). p value denotes ANOVA with Bonferroni's multiple comparisons test. Scale bar, 300 μm H, MDA-MB-231Cas9 cells with PITPβ KO and control non-targeted KO were transfected with control siRNAs or siRNAs against PITPα, PITPβ, or both PITPα and PITPβ. After 24 h, cells were treated with 30 μM cisplatin or vehicle for 24 h before being processed for Crystal Violet viability assay. The cells were imaged by an EVOS M5000 microscope. Scale bar, 300 μm. See quantification in Fig. S9B. I, MDA-MB-231 cells were transfected with control siRNAs or siRNAs against p53, PITPα, PITPβ, PITPNC1, or both PITPα and PITPβ. After 24 h, cells were treated with 30 μM cisplatin or vehicle for 24 h before being processed for a caspase 3 activity assay. p value denotes ANOVA with Bonferroni's multiple comparisons test. For all panels, n = 3 independent experiments and data are presented as the mean ± SD. PITPα/β regulate p53-dependent nuclear Akt activation and cell survival.A and B, MDA-MB-231 cells were transfected with control siRNAs or siRNAs against PITPα, PITPβ, PITPNC1, or both PITPα and PITPβ. After 24 h, cells were treated with 30 μM cisplatin or vehicle for 24 h before being processed for IF staining against pAktS473. The nuclear pAktS473 levels were quantified by ImageJ (B). n = 3, average values were calculated from 15 cells from each independent experiment. p value denotes ANOVA with Bonferroni's multiple comparisons test. Scale bar, 5 μm. C–E, BT-549, SUM159, and SUM1315 cells with the indicated p53 status were transfected with control siRNAs or siRNAs against both PITPα and PITPβ. After 24 h, cells were treated with 30 μM cisplatin or vehicle for 24 h before being processed for IF staining against pAktS473. The nuclei were counterstained by DAPI. The nuclear pAktS473 levels were quantified by ImageJ (D). n = 3, average values were calculated from 15 cells from each independent experiment. Scale bar, 5 μm. The double KD of PITPα and PITPβ in SUM159 cells was validated by WB (E). See KD validation for BT-549 and SUM1315 cells in Fig. S9, H and J. F and G, MDA-MB-231 cells were transfected with control siRNAs or siRNAs against p53, PITPα, PITPβ, PITPNC1, or both PITPα and PITPβ. After 24 h, cells were treated with 30 μM cisplatin or vehicle for 24 h before being processed for Crystal Violet viability assay. The cells were imaged by an EVOS M5000 microscope (F) and quantified based on the extracted dye using a plate reader (G). p value denotes ANOVA with Bonferroni's multiple comparisons test. Scale bar, 300 μm H, MDA-MB-231Cas9 cells with PITPβ KO and control non-targeted KO were transfected with control siRNAs or siRNAs against PITPα, PITPβ, or both PITPα and PITPβ. After 24 h, cells were treated with 30 μM cisplatin or vehicle for 24 h before being processed for Crystal Violet viability assay. The cells were imaged by an EVOS M5000 microscope. Scale bar, 300 μm. See quantification in Fig. S9B. I, MDA-MB-231 cells were transfected with control siRNAs or siRNAs against p53, PITPα, PITPβ, PITPNC1, or both PITPα and PITPβ. After 24 h, cells were treated with 30 μM cisplatin or vehicle for 24 h before being processed for a caspase 3 activity assay. p value denotes ANOVA with Bonferroni's multiple comparisons test. For all panels, n = 3 independent experiments and data are presented as the mean ± SD. PITPα/β-mediated p53-PIPn signaling requires PI transfer activity As PITPα/β exchange PI for PC, we investigated whether the PI transfer activity of these PITPs was required to regulate p53 levels and nuclear Akt activation. For this, we utilized the PITPα/βT59D mutant that specifically disrupts PI binding (44, 45, 46). Ectopically expressed HA-tagged PITPα/βwt interacted with p53wt and mutant p53R175H, while the corresponding PITPα/βT59D mutants exhibited impaired interaction with p53 (Figs. 6A and S10, A–C). MST analysis of PITPαwt and PITPαT59D with p53 validated these observations, as well as the PI-binding deficiency of PITPαT59D, suggesting conformational changes due to PI loading into the class I PITPs impacts their interaction with p53 (Table 3 and Fig. S10, D–G). Moreover, the reduction in the stress-induced p53 protein and nuclear pAktS473 levels by combined PITPα and PITPβ KD using distinct siRNAs targeting their 3′-UTR was rescued by expression of PITPαwt, but not mutant PITPαT59D (Fig. 6, B–D). Notably, nuclear pAktS473 levels correlated with the content of re-expressed PITPαwt, but not mutant PITPαT59D (Fig. 6, E and F), indicating that the generation of p53-PIPn complexes is PITPαwt dose-dependent.Figure 6PITPα/β initiate the p53-PIPn signalosome by a PI binding-dependent mechanism.A, HEK293FT cells were co-transfected with either HA-tagged wild-type PITPα or PI binding-defective mutant T59D PITPα together with Flag-tagged p53wt. After 48 h, cells were processed for IP against Flag-tag and analyzed by WB. p value denotes two-sided paired t test. B–D, MDA-MB-231 cells were transfected with control siRNAs or siRNAs against the 3′UTR of both PITPα and PITPβ for 24 h. Then, the cells were transfected with either HA-tagged wild-type PITPα/β or PI binding-defective mutant T59D PITPα/β. After 24 h, cells were treated with 30 μM cisplatin or vehicle for 24 h before being processed for WB (C) and IF staining against HA-tag with pAktS473 (D). The nuclear pAktS473 levels in HA-positive cells were quantified by ImageJ (E). n = 3, average values were calculated from 15 cells from each independent experiment. p value denotes two-sided paired t test. Scale bar, 5 μm. E and F, Pearson’s correlation coefficient (Pearson’s r) quantified the correlations between nuclear pAktS473 and HA-PITPαwt/T59D levels. n = 100 cells pooled from 3 independent experiments. G and H, MDA-MB-231 cells were transfected with control siRNAs or siRNAs against the 3′UTR of both PITPα and PITPβ for 24 h. The cells were then transfected with either HA-tagged wild-type PITPα or PI binding-defective mutant T59D PITPα. After 24 h, cells were treated with 30 μM cisplatin or vehicle for 24 h before being processed for Crystal Violet viability assay. The cells were imaged by an EVOS M5000 microscope (H) and quantified based on the extracted dye using a plate reader (I). p value denotes two-sided paired t test. Scale bar, 300 μm. For all panels, n = 3 independent experiments and data are presented as the mean ± SD.Table 3MST analysis of PITPαwt and PITPαT59D, The interaction of recombinant fluorescently labelled PITPαwt and PITPαT59D with other components was quantitated by MST assayMicroscale thermophoresis (MST)TargetKd with PITPαwt (Kd) PI28 ± 2.7 nM p531.23 ± 0.05 nMTargetKd with PITPαT59D (Kd) PI2340 ± 219 nM p5311.7 ± 1 nMA constant concentration of fluorescently labelled PITPαwt/T59D (5 nM) was incubated with increasing concentrations of non-labelled ligand and analyzed using a Monolith NT.115 pico, and the binding affinity was autogenerated by MO. Control v.1.6 software. Data are presented as the mean ± SD. PI supplied as micelles. PITPα/β initiate the p53-PIPn signalosome by a PI binding-dependent mechanism.A, HEK293FT cells were co-transfected with either HA-tagged wild-type PITPα or PI binding-defective mutant T59D PITPα together with Flag-tagged p53wt. After 48 h, cells were processed for IP against Flag-tag and analyzed by WB. p value denotes two-sided paired t test. B–D, MDA-MB-231 cells were transfected with control siRNAs or siRNAs against the 3′UTR of both PITPα and PITPβ for 24 h. Then, the cells were transfected with either HA-tagged wild-type PITPα/β or PI binding-defective mutant T59D PITPα/β. After 24 h, cells were treated with 30 μM cisplatin or vehicle for 24 h before being processed for WB (C) and IF staining against HA-tag with pAktS473 (D). The nuclear pAktS473 levels in HA-positive cells were quantified by ImageJ (E). n = 3, average values were calculated from 15 cells from each independent experiment. p value denotes two-sided paired t test. Scale bar, 5 μm. E and F, Pearson’s correlation coefficient (Pearson’s r) quantified the correlations between nuclear pAktS473 and HA-PITPαwt/T59D levels. n = 100 cells pooled from 3 independent experiments. G and H, MDA-MB-231 cells were transfected with control siRNAs or siRNAs against the 3′UTR of both PITPα and PITPβ for 24 h. The cells were then transfected with either HA-tagged wild-type PITPα or PI binding-defective mutant T59D PITPα. After 24 h, cells were treated with 30 μM cisplatin or vehicle for 24 h before being processed for Crystal Violet viability assay. The cells were imaged by an EVOS M5000 microscope (H) and quantified based on the extracted dye using a plate reader (I). p value denotes two-sided paired t test. Scale bar, 300 μm. For all panels, n = 3 independent experiments and data are presented as the mean ± SD. Table 3MST analysis of PITPαwt and PITPαT59D, The interaction of recombinant fluorescently labelled PITPαwt and PITPαT59D with other components was quantitated by MST assayMicroscale thermophoresis (MST)TargetKd with PITPαwt (Kd) PI28 ± 2.7 nM p531.23 ± 0.05 nMTargetKd with PITPαT59D (Kd) PI2340 ± 219 nM p5311.7 ± 1 nMA constant concentration of fluorescently labelled PITPαwt/T59D (5 nM) was incubated with increasing concentrations of non-labelled ligand and analyzed using a Monolith NT.115 pico, and the binding affinity was autogenerated by MO. Control v.1.6 software. Data are presented as the mean ± SD. PI supplied as micelles. MST analysis of PITPαwt and PITPαT59D, The interaction of recombinant fluorescently labelled PITPαwt and PITPαT59D with other components was quantitated by MST assay A constant concentration of fluorescently labelled PITPαwt/T59D (5 nM) was incubated with increasing concentrations of non-labelled ligand and analyzed using a Monolith NT.115 pico, and the binding affinity was autogenerated by MO. Control v.1.6 software. Data are presented as the mean ± SD. PI supplied as micelles. The cytotoxicity and sensitization to cisplatin-induced apoptosis by combined PITPα/β KD using the 3′-UTR targeting siRNAs were partly rescued by re-expressing PITPαwt but not the PITPα/βT59D mutant (Figs. 6, G and H and S11A). These results demonstrate that the PI transfer activity of class I PITPs regulates their interaction with p53, p53 stability, and subsequent nuclear Akt activation. Combined PITPα/β KD also inhibited EGF-stimulated cell invasion, and these effects were partly restored by re-expressing PITPαwt but not the PITPαT59D mutant (Fig. S11, B and C), consistent with reports that PITPs contribute to EGF signaling (47). The data indicate that PITPα/β regulate cell growth, invasion, and protection against genotoxic stress (Fig. 7A), although elucidation of the underlying mechanisms will require additional investigation.Figure 7Lipid transfer proteins and PI4KIIα initiate nuclear p53-phosphoinositide signaling. A model of the PITP- and PI4KIIα-dependent initiation of the nuclear p53-PI signalosome, which promotes cell proliferation, survival, and invasion. The PITP and PI4KIIα form complexes with p53 that are necessary for the assembly of the p53-PI4P complex that is further phosphorylated by PIP kinases and then assembles the full Akt pathway kinases on p53. PDK1, 3-phosphoinositide-dependent kinase 1. mTORC2, mechanistic Target of Rapamycin Complex 2. Lipid transfer proteins and PI4KIIα initiate nuclear p53-phosphoinositide signaling. A model of the PITP- and PI4KIIα-dependent initiation of the nuclear p53-PI signalosome, which promotes cell proliferation, survival, and invasion. The PITP and PI4KIIα form complexes with p53 that are necessary for the assembly of the p53-PI4P complex that is further phosphorylated by PIP kinases and then assembles the full Akt pathway kinases on p53. PDK1, 3-phosphoinositide-dependent kinase 1. mTORC2, mechanistic Target of Rapamycin Complex 2. Discussion Here, we reveal an unexpected role for class I PITPα/β in generating nuclear p53-PIPn complexes that initiate nuclear PIPn signaling. Although the existence of nuclear PIPns and their role in the cell cycle (48), oxidative stress (16, 49, 50, 51, 52, 53, 54), and the DNA damage response (17, 55, 56, 57) is supported by growing evidence (16), the molecular regulators of nuclear PIPns in regions devoid of membranes have been enigmatic (58). PITPs have a well-established role in transporting PI from the endoplasmic reticulum to membranes, enabling membrane-localized PIPn signaling via PIP kinases, phosphatases, and phospholipases (25, 59, 60, 61, 62, 63). The findings presented here demonstrate that class I PITPs accumulate in the nucleus and bind p53 by a genotoxic stress-regulated mechanism. As such, these data expand the roles of the PITPα/β lipid transport activities that were thought to act solely at cytosolic membranes and establish their mechanistic roles in generating nuclear p53-PIPn complexes. PITPα/β, but not other PITP family members, bind directly to p53wt and p53mt with high affinity and these interactions are enhanced by cell stress. This complex also includes the small heat shock proteins (Hsp27 and αB-crystallin), which stabilize p53 (18). PITPα/β binding to p53 is necessary for the linkage of PIPns with p53 (p53-PIPn signalosome). Once the p53-PIPn complex is formed, it is stable, detected by PIPn isomer antibodies, and acted on by multiple PIP kinases and phosphatases, indicating that the myo-inositol head group is accessible, a characteristic that distinguishes these complexes from conventional protein-PIPn binding (17, 18, 31). The p53-PIPn signalosome culminates in the formation of p53-PI3,4,5P3 complexes that, in turn, recruit and activate Akt in the nucleus, conferring resistance to stress-induced apoptosis (17). However, PITPs also contribute to the canonical membrane-localized PI3K/Akt pathway (64), so the observed differences in cellular phenotypes by PITPα/β KD likely reflect some contribution of both the canonical and the nuclear PI3K/Akt pathways. These PITPα/β activities require PI binding, underscoring the critical functional role of lipid transport as a mechanism to establish nuclear PIPns. The ability of wild-type PITPα, but not the PI-binding-defective mutant, to rescue the phenotype of combined PITPα/β KD suggests a functional redundancy between the class I PITPs. This is consistent with previous reports that either PITPα or PITPβ is sufficient to rescue the phenotype of double PITPα/β knockout in a PI-binding dependent manner (44, 65). PITPα/β also binds to PI4KIIα, and the addition of p53 protein increases the affinity between PITPs and PI4KIIα, which supports the formation of a ternary complex. As both PITPα/β and PI4KIIα are required to generate p53-PI4P, these data point to a functional collaboration between PITPα/β and PI4KIIα in initiating nuclear p53-PIPn signaling that is reminiscent of their roles in generating PI4P in the membrane-localized pathway (38, 39), although likely employing unique mechanisms that result in a p53-PIPn linkage. Remarkably, PITPα/β and PI4KIIα regulate the association of PIPns to p53 in a manner that is inconsistent with traditional protein-PIPn interactions. Conventional protein-PIPn interactions are electrostatic in nature and are disrupted by denaturation and SDS-PAGE, yet p53-PIPn complexes remain intact following these interventions (17, 18). Previous studies have demonstrated that the p536Q CTD mutant has diminished binding to PIPns (17, 18), but formation of the p536Q -PI4P complex is enhanced, further distinguishing these complexes from conventional p53-PIPn binding. Perhaps most significantly, the p53-linked PIPns maintain signaling competency as they are modified by kinases and phosphatases and remain detectable via antibody recognition of an exposed phospho-inositol headgroup. In contrast to p53-PIPn complexes, most protein-PIPn interactions involve direct binding of the headgroup to protein domains, precluding the lipid phospho-inositol headgroup from kinase or phosphatase modification (66, 67), underscoring this unique characteristic of p53-PIPn complexes. The data presented here indicate that PIPn second messengers, beginning with PI4P, are linked to p53 by the combined activities of PITPα/β and PI4KIIα. The resulting p53-PI4P is acted on by PIP kinases and phosphatases such that the p53-PI3,4,5P3 complex functions as a nuclear messenger to recruit PDK1, mTORC2, and Akt (17). Notably, each of these proteins is known to interact with the PIPn head group. In the case of mutant p53 proteins, p53 activation may contribute to its oncogenic gain-of-function activity by activating nuclear Akt and suppressing apoptosis. Additionally, this prosurvival activity may counteract the proapoptotic function of wild-type p53 and represent a novel mechanism for wild-type p53 to confer stress-resistance, consistent with prior reports of its ability to regulate metabolism, oxidative stress and DNA damage (68). These findings suggest a “third messenger” pathway (17) with p53 as the founding member whereby PIPn second messengers are linked to cellular proteins in membrane-free regions and modified by PIP kinases/phosphatases to regulate their function (Fig. 7A). As detailed in the companion paper (43), many other proteins are PIPn-linked by a PITP/PI4KIIα-dependent mechanism, thereby providing crucial evidence of an emerging third messenger pathway. Given the critical role of class I PITPs in initiating nuclear phosphoinositide signaling, which attenuates cellular stress and apoptosis, these findings also point to these PITPs and PI4KIIα as potential therapeutic targets in a variety of diseases, including cancer. Experimental procedures Cell culture and constructs A549, BT-549, Cal33, HCT116, HS578T, MDA-MB-231, SUM159, SUM1315, HEK293FT, and MCF-10A cells were purchased from ATCC. MCF10A cells were cultured in DMEM/F12 (#11330-032, Invitrogen) supplemented with 10% fetal bovine serum (#SH30910.03, Hyclone), 1% penicillin/streptomycin (#15140-122, Gibco), 20 ng/ml EGF (#CC-4107, Lonza), 0.5 mg/ml Hydrocortisone (#H4001, Sigma), 100 ng/ml Cholera toxin (#C-8052, Sigma), and 10 μg/ml Insulin (#I-1882, Sigma). The other cells were maintained in DMEM (#10-013-CV, Corning) supplemented with 10% fetal bovine serum (#SH30910.03, Hyclone) and 1% penicillin/streptomycin (#15140-122, Gibco). The Flag-tagged p53 constructs and corresponding PIPn-binding-defective 6Q mutants in this work have been described previously (18). The HA-tagged wild-type PITPα/β constructs and PI-binding deficient mutants T59D (44) were purchased from Genscript. Plasmids were transfected into mammalian cells using Lipofectamine3000, (#L3000015, Thermo Fisher Scientific) according to the manufacturer’s instructions. Typically, 2 to 5 μg of DNA and 6 to 10 μl of lipid were used for transfecting cells in 6-well plates. Cells with at least 80% transfection efficiency were used for further analysis. Antibodies and reagents Monoclonal antibodies against p53 (clone DO-1, #SC-126, Santa Cruz Biotechnology), p53 (clone 7F5, #2527, Cell Signaling), pAktS473 (clone 193H12, #4058, Cell Signaling), HA-tag (clone C29F4, #3724, Cell Signaling), Flag-tag (clone D6W5B, #14793, Cell Signaling), GAPDH (clone 0411, #sc-47724, Santa Cruz Biotechnology), Lamin B2 (clone D8P3U, #12255, Cell Signaling), EGFR (clone D6B6, #2085, Cell Signaling), HSP27 (clone D6W5V, #95357, Cell Signaling), and polyclonal antibodies against PITPα (#16613-1-AP, ThermoFisher), PITPβ (#ab127563, abcam), PITPNC1 (IF, #ab222078, abcam), PITPNC1 (WB, #NBP2-19842, Novus), PITPNM1 (#26983-1-AP, Proteintech), PITPNM2 (#PA5-48616, Invitrogen), pAktT308 (#9275, Cell Signaling), PI4KIIα (#NBP2-44158, Novus), PI4KIIIα (#4902S, CST), PI4KIIβ (#PA5-82133, Thermo), PI4KIIIβ (#ab134756, abcam), and αB-Crystallin (#ADI-SPA-223-F, Enzo) were used in this study. For conventional immunostaining and PLA analysis of phosphoinositides, anti-PI4P (#Z-P004), PI4,5P2 (#Z-P045), and PI3,4,5P3 (#Z-P345) antibodies were purchased from Echelon Biosciences. For immunoblotting analyses, antibodies were diluted at a 1:1000 ratio except for p53 (clone DO-1, 1:5000) and GAPDH (clone 0411, 1:5000). For immunoprecipitation, antibody-conjugated agarose was purchased from Santa Cruz Biotechnology, including agarose-conjugated antibodies against p53 (#sc-126AC), PITPα/β (#sc-398050AC), HA-tag (#sc-7392AC), and Flag-tag (#sc-166355AC). For immunostaining analyses and proximity ligation assay (PLA), antibodies were diluted at a 1:100 ratio. The nuclear envelope marker (Alexa Fluor488 Lamin A/C, clone 4C11, #8617, Cell Signaling, 1:200) examined subnuclear regions. For the KD experiments, the ON-TARGETplus siRNA SMARTpool with four siRNAs in combination against human p53 (#L-003329-00), PITPα (#L-018010-00), PITPβ (#L-006459-01), and PITPNC1 (#L-012476-02) were purchased from Dharmacon. Non-targeting siRNA (#D-001810-01, Dharmacon) was used as a control. For the KD and rescue experiments, pooled-siRNAs targeting the 3′UTR of PITPα (sense 5′-AGGCAACUUUCGAUUCCUUACUGUA-3′ and antisense 5′-UACAGUAAGGAAUCGAAAGUUGCCU-3′; sense 5′-CCGUCUCUCUCCAUUGUGUUCCGAU-3′ and antisense 5′-AUCGGAACACAAUGGAGAGAGACGG-3′) and pooled-siRNAs targeting the 3′UTR of PITPβ (sense 5′-GAGUGAACAACAAUCUGACCAGUAU-3′ and antisense 5′-AUACUGGUCAGAUUGUUGUUCACUC-3′; sense 5′-CUACAAAGCUGAUGAAGAC-3′ and antisense 5′-GUCUUCAUCAGCUUUGUAG-3′) were purchased from Thermo Fisher Scientific. The siRNAs were delivered to cells by RNAiMAX reagent (#13778150, Thermo Fisher Scientific), and KD efficiency was determined by immunoblotting. KD efficiency greater than 80% was required to observe phenotypic changes in the study. Cisplatin (#NC1706394, Fisher Scientific), etoposide (#S1225, Sellekchem), Erastin (#S7242, Selleckchem), tert-Butylhydroquinone (tBHQ, #SPCM-T1540-06, Spectrum), and hydroxyurea (HU, #1332000, Millipore Sigma) were used as cellular stressors. Nutlin 3a (#S8059, Sellekchem), PI-273 (#AOB37765, aobious), and NC03 (#AOB17420, aobious) were also used. Immunoprecipitation and immunoblotting Cells were removed from the medium after the indicated treatment, washed three times with ice-cold PBS, and lysed in an ice-cold RIPA lysis buffer system (#sc-24948, Santa Cruz Biotechnology) with 1 mM Na3VO4, 5 mM NaF, and 1x protease inhibitor cocktail (#11836153001, Roche). The cell lysates were then sonicated followed by incubation at 4 °C with continuous rotation for 1 h and centrifuged at maximum speed for 10 min to collect the supernatant. The protein concentration in the supernatant was measured by the Bradford protein assay (#5000201, BIO-RAD). All antibodies were diluted at a 1:1000 ratio for immunoblotting unless otherwise indicated. For immunoprecipitation, 0.5 to 1 mg of protein was incubated with 20 μl of antibody-conjugated agarose (Santa Cruz Biotechnology) at 4 °C for 24 h. After washing three times with PBST (PBS with 0.1% Tween 20), the protein complex was eluted with SDS sample buffer and boiled at 95 °C for 10 min. For immunoblotting, 5 to 20 μg of protein were loaded. For immunoblotting of immunoprecipitated complexes, horseradish peroxidase (HRP)-conjugated antibodies were used to avoid non-specific detection of immunoglobulin in the immunoprecipitated samples. HRP-conjugated p53 (#sc-126HRP), PITPα (#sc-13569HRP), and PITPβ (#sc-390500HRP) antibodies were purchased from Santa Cruz Biotechnology. Immunoblots were developed by Odyssey Imaging System (LI-COR Biosciences), and the intensity of protein bands was quantified using ImageJ. Statistical data analysis was performed with Microsoft Excel, using data from at least three independent experiments. Fluorescent IP-WB Cells were lysed in a RIPA lysis buffer system (17), and lysates were incubated with 20 μl anti-p53 (#sc-126 AC, Santa Cruz Biotechnology) mouse monoclonal IgG antibody-conjugated agarose at 4 °C for 24 h. Normal immunoglobulin (IgG)-conjugated agarose was used as a negative control (#sc-2343, Santa Cruz Biotechnology). The protein complex was eluted with SDS sample buffer and boiled at 95 °C for 10 min. For immunoblotting, 5 to 20 μg of protein were loaded. The protein complexes were analyzed via WB as described above. For double fluorescent IP-WB detecting p53-PI4P/PI4,5P2/PI3,4,5P3 complexes, anti-p53 rabbit monoclonal IgG antibody (clone 7F5, #2527, Cell Signaling) at 1:2000 dilution and anti-PI4P mouse monoclonal IgM antibody (#Z-P004, Echelon Biosciences), PI4,5P2 mouse monoclonal IgM antibody (#Z-P045, Echelon Biosciences), or PI3,4,5P3 mouse monoclonal IgM antibody (#Z-P345, Echelon Biosciences) at 1:1000 dilution were mixed in blocking buffer with 0.02% Sodium Azide and incubated with the membrane at 4 °C overnight. For the secondary antibody incubation, goat anti-rabbit IgG antibody conjugated with IRDye 800CW fluorophore (#926-32211, LI-COR) and goat anti-mouse IgM antibody conjugated with IRDye 680RD fluorophore (#926-68180, LI-COR) at 1:10,000 dilution were mixed in blocking buffer with 0.01% SDS and 0.1% Tween 20 and incubated with the membrane at room temperature for 2 h. The images were subsequently acquired simultaneously using the 700 and 800 nm wavelength channels on the Odyssey Fc Imaging System (LI-COR Biosciences). Statistical data analysis was performed with Microsoft Excel, using data from at least three independent experiments. Immunofluorescence (IF) and confocal microscopy For immunofluorescence studies, cells were grown on coverslips coated with 0.2% gelatin (#G9391, Millipore Sigma). Cells were fixed with 4% paraformaldehyde (PFA) (#sc-281692, Santa Cruz Biotechnology) for 20 min at room temperature, then washed three times with PBS. Next, the cells were permeabilized with 0.3% Triton-X100 for 30 min to permeate the nuclear envelope thoroughly and were rewashed three times with PBS. The cells were then blocked with 1% BSA in PBS for one hour at room temperature. After blocking, cells were incubated with primary antibodies overnight at 4 °C. The cells were then washed three times with PBS and incubated with fluorescent-conjugated secondary antibodies (Molecular Probes) for 1 h at room temperature. After secondary antibody incubation, the cells were washed three times. Then the coverslips were removed from the dishes, air-dried for 10 min at room temperature and mounted in Prolong Glass Antifade Mountant with NucBlue Stain (#P36985, Thermo Fisher Scientific). The images were taken by a Leica SP8 3xSTED Super-Resolution Microscope, a point scanning confocal, and a 3xSTED super-resolution microscope using LASX software (Leica Microsystems). All images were acquired using the 100X objective lens (N.A. 1.4 oil). The z-stack images were taken with each frame of 0.2 μm thickness. For quantification, the mean fluorescent intensity of channels in each cell was measured by LASX. GraphPad Prism Version 9.4.1 generated quantitative graphs. The images were processed using ImageJ. The correlation of double-staining channels was quantified by GraphPad Prism using Pearson’s correlation coefficient (Pearson’s r), ranging between 1 and −1. Proximity ligation assay (PLA) PLA was utilized to detect in situ protein-protein/PIPn interaction or close proximity, as previously described (17, 18, 31). After fixation and permeabilization, cells were blocked before incubation with primary antibodies as in routine IF staining. The cells were then processed for PLA (#DUO92101, MilliporeSigma) according to the manufacturer’s instruction and previous publications (17, 18, 31). Post-PLA slides were further processed for immunofluorescent staining against the nuclear membrane marker (Lamin A/C, #8617, Cell Signaling). After washing, the slides were processed and imaged as indicated in the IF section above. The Leica SP8 confocal microscope detected PLA signals as discrete punctate foci and provided the intracellular localization of the complex. ImageJ was used to quantify the nuclear PLA foci. Crystal violet cell viability assay In 96-well plates, 5 × 104 cells/well of MDA-MB-231, MDA-MB-231Cas9, BT549, SUM159, or SUM1315 cells were transfected with control siRNAs or siRNAs targeting p53, PITPα, PITPβ, PITPNC1, or the combination of PITPα and PITPβ as indicated for 48 h. For the KD rescue experiments, MDA-MB-231 cells were transfected with control siRNAs or siRNAs targeting 3′UTR of PITPα and PITPβ for 24 h. Next, the cells were transfected with HA-tagged wild-type PITPα or its PI-binding-deficient T59D mutant PITPα for another 24 h. The cells were then treated with the control vehicle or 30 μM cisplatin for 24 h, and the cells were subsequently fixed with 4% PFA and stained with 0.2% Crystal Violet. After washing, the plates were air-dried at room temperature and imaged using the EVOS M5000 Imaging System (ThermoFisher Scientific). The dye was extracted from the cells with 10% acetic acid and quantified by measuring the absorbance at 570 nm using a Synergy HTX Multi-Mode Microplate reader. Caspase 3 activity assay In 6-well plates, 1 × 106 cells/well of MDA-MB-231, BT549, SUM159, or SUM1315 were transfected with control siRNAs or siRNAs targeting p53, PITPα, PITPβ, PITPNC1, or the combination of PITPα and PITPβ as indicated for 48 h. For the KD rescue experiments, MDA-MB-231 cells were transfected with control siRNAs or siRNAs targeting 3′UTR of PITPα and PITPβ for 24 h. Then, the cells were transfected with either HA-tagged wild-type PITPα or its PI-binding-deficient T59D mutant PITPα for another 24 h, followed by treatment with a control vehicle or 30 μM cisplatin for 24 h. Next, the cells were lysed and processed for a Caspase 3 activity assay following the manufacturer’s instructions (#E-13183, Thermo Fisher Scientific). The fluorescence was read at excitation/emission 342/441 nm using a Synergy HTX Multi-Mode Microplate reader. Microscale thermophoresis (MST) assay The microscale thermophoresis (MST) assay was used to calculate the binding affinities of purified recombinant proteins (p53 (#81091, Active Motif), PITPα (#ab101666, Abcam), PITPβ (#LS-C794864, LSBio), PITPNC1 (#LS-G33119-10, LSBio) PI4KIIα (lab-made)) and other contributing factors in vitro as previously described (69). Following the manufacturer's instructions, the target protein was fluorescently labeled using a Monolith Protein Labeling kit (RED-NHS second-generation MO-L011, Nano Temper). Then, sequential titration of unlabeled ligand proteins or PI (#840042P, Avanti), was made in a Tris-based MST buffer and mixed with an equal volume of fluorescently labelled target protein prepared at 10 nM concentration in the same MST buffer, making the final target protein at a constant concentration of 5 nM and the ligand-protein or lipid as the gradient. For PI cofactor analysis, target proteins were mixed with 1 μM PI before ligand proteins. The target–ligand mixtures were loaded into Monolith NT.115 series capillaries (MO-K022, Nano Temper), and the MST traces were measured using Monolith NT.115 pico. The binding affinity was auto-generated using MO Control v.1.6 software. In vitro binding assay The recombinant proteins p53 (#81091, Active Motif), PITPα (#ab101666, Abcam), PITPβ (#ab101091, Abcam), and PI4KIIα (lab made) were used for In vitro binding assays. The binding assay was performed in PBS by incubating a constant amount of p53 or PI4KIIα with an increasing amount of p53, PITPα/β, or PI4KIIα in the presence of 20 μl anti-p53 antibody-conjugated agarose (#sc-126AC, Santa Cruz). After incubating overnight at 4 °C, unbound proteins were removed by washing three times with PBST, and the protein complex was analyzed by immunoblotting. Nuclear fractionation Nuclear fractionation was used to analyze compartmentalized protein expression. MDA-MB-231 cells were processed using the NE-PER nuclear and cytoplasmic extraction reagents (#78833, Thermo) according to the manufacturer’s instructions. Cells were manually removed from their culture dishes into suspension, and the cytosolic extraction reagent was used to isolate cytosolic fractions. Then, the nuclear extraction reagent was used to produce the nuclear fraction. Lenti-CRISPR gene editing CRISPR-Cas9 genome editing was used to knock out the gene encoding PITPβ in MDA-MB-231 cells. First, a Cas9-expressing stable cell line was generated by transducing cells with viral particles (#LVCAS9BST, Sigma Aldrich) at a multiplicity of infection (MOI) of 0.5. Transduction was performed in complete media containing 8μg/ml polybrene. After 24 h incubation, Cas9-expressing cells were selected with 10μg/ml blasticidin (#DSB12150; Dot Scientific) for 1 week, and expression was confirmed. To generate PITPβ KO cells, viral particles containing the guide RNA sequence for PITPβ (5′-CAATCATCCTCACGAATGC-3′) and negative control (5′-CGCGATAGCGCGAATATATT-3′) were purchased from Sigma Aldrich. Sequences were cloned into LV21 lentiviral vectors (Sigma Aldrich). Cas9-expressing cells were then transduced with viral particles at a MOI of 0.5 and incubated for 24 h. Transduction was performed in the presence of 8μg/ml polybrene in complete media. Media was removed 24 h after viral transduction and 1500 μg/ml geneticin (#10131035; Sigma Aldrich) was added for selection. After 1 week of selection in antibiotics, single cells were isolated in the 96-well tissue culture dish by BD FACS AriaII. Transwell invasion assay The bottom polycarbonate filter surface of a 6.5 mm diameter insert with 8 μm pores in a 24-well plate (#3422, Corning) was coated with 10 μg/ml of Laminin (#CC095, Millipore Sigma) diluted in PBS for 3 h at 37 °C. MDA-MB-231 cells were transiently transfected with control siRNAs or siRNAs targeting the 3′UTR of both PITPα and PITPβ for 24 h. Then, the cells were transfected with either HA-tagged wild-type PITPα or its PI-binding-deficient T59D mutant PITPα. After 24 h, cells were serum-starved for an additional 24 h. Next, 5 × 104 transfected cells were suspended in 200 μl serum-free medium containing 0.5% BSA and then were plated in the upper insert chamber in 500 μl serum-free medium with 0.5% BSA. 10 ng/ml EGF was added to the lower chamber. Cells were allowed to invade for 16 h at 37 °C. Cells on the bottom of the filter were then fixed with 4% PFA and stained with 0.2% Crystal Violet. The stained cells were imaged using the EVOS M5000 Imaging System (ThermoFisher Scientific). At the end of the assay, the dye was extracted by 10% acetic acid from the cells and quantified by measuring the optical density at 570 nm using a Synergy HTX Multi-Mode Microplate reader. [3H]myo-inositol metabolic labeling Cells were split and cultured in low serum Opti-MEM (#31985070, Thermo) supplemented with 10% dialyzed FBS with a 10,000 mw cut-off (#F0392, Sigma) and 1% Pen/strep (#15140-122, Gibco) to minimize inositol in the culture media. In 10 cm dishes, 0.5 × 106 MDA-MB-231 cells were seeded to achieve ∼5% confluency the following day. 24 h after plating, cells were treated with either 1.322 μM (25 μCi/ml) of [3H]myo-inositol (#NET1156005MC, PerkinElmer) or unlabeled myo-inositol (#J60828.22, Thermo) and allowed to uptake the metabolic label for 48 h. For KD experiments, PITPα/β siRNAs were added and recovered as normal and fresh [3H]myo-inositol supplemented media was used to replace the transfection media. 24 h after siRNA transfection (72 h after original plating), cells were treated with control vehicle or 30 μM cisplatin for another 24 h. Labeled and unlabeled cells were then lysed and p53 was immunoprecipitated as described in immunoprecipitation and immunoblotting, before performing SDS-PAGE or CHCl3/MeOH extraction as indicated. For extraction, MeOH:CHCl3 (2:1) was added to RIPA cell lysates to form the protein precipitate. Soluble phases in MeOH and CHCl3 were aspirated out and the protein flake was dried using a speed vacuum. Protein samples were then resuspended and solubilized in PBS with sonication. SDS-PAGE samples were excised from the gel, and each lane was either further sectioned or treated as a whole and dissolved in 30% H2O2 before liquid scintillation counting (LSC). Dissolved gel samples or resuspended protein samples from the CHCl3/MeOH extraction were added to LSC vials with LSC cocktail (#6013319, PerkinElmer) before being processed by PerkinElmer Tri-Carb 4910 TR liquid scintillation analyzer. Analysis and DPM calculation were automated using QuantaSmart software. qPCR assay Total RNA was extracted by RNeasy kits (QIAGEN). The cDNA was synthesized using High-Capacity RNA-to-cDNA kits (Applied Biosystems). qPCR assays were performed using PowerUp SYBR Green Master Mix for qPCR (Applied Biosystems). The mRNA expression of genes was normalized with the β-actin gene. The primer sequences are as follows: PITPNA (F; CAAGGAGTATCGAGTAATCCTGC, R; GCCACCACCCGTTTCATTTT), PITPNB (F; CTGTTCAGGAGTATCAGGTTGGG, R; GGCACTTTGCTCTTTAGGTGA), TP53 (F; CAGCACATGACGGAGGTTGT, R; TCATCCAAATACTCCACACGC), and β-actin (F; CATGTACGTTGCTATCCAGGC, R; CTCCTTAATGTCACGCACGAT). Statistics and reproducibility Two-tailed unpaired t-tests were used for pair-wise significance, and one-way ANOVA was used for group significance with Bonferroni's multiple comparisons test used for significance within grouped samples. We note that no power calculations were used. Sample sizes were determined based on previously published experiments where significant differences were observed (17, 18). We used at least three independent experiments or biologically independent samples for statistical analysis. Data availability To allow others to replicate and build on this work, we will make all materials, data, and associated protocols available to readers in a public repository upon publication. Supporting information This article contains supporting information. Conflict of interest The authors declare that they have no conflicts of interest with the contents of this article.